Structure Therapeutics (NASDAQ:GPCR) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note published on Monday morning, Benzinga reports. The firm currently has a $65.00 price target on the stock.

A number of other equities research analysts also recently commented on the company. JMP Securities cut their price objective on Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating for the company in a research report on Friday, August 9th. BMO Capital Markets boosted their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an outperform rating in a research note on Friday, June 7th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Structure Therapeutics in a research note on Tuesday, May 21st. They set an overweight rating and a $65.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics presently has an average rating of Buy and an average target price of $84.63.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $40.00 on Monday. Structure Therapeutics has a one year low of $26.61 and a one year high of $75.02. The stock has a fifty day moving average of $38.18 and a 200-day moving average of $39.67. The company has a market capitalization of $1.86 billion, a PE ratio of -51.95 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. As a group, research analysts forecast that Structure Therapeutics will post -0.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC increased its stake in shares of Structure Therapeutics by 4.5% in the second quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock worth $567,000 after acquiring an additional 617 shares during the last quarter. Sandia Investment Management LP acquired a new position in shares of Structure Therapeutics in the second quarter worth $39,000. Brandywine Managers LLC increased its stake in shares of Structure Therapeutics by 9.2% in the fourth quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock worth $489,000 after acquiring an additional 1,007 shares during the last quarter. Quarry LP acquired a new position in shares of Structure Therapeutics in the second quarter worth $79,000. Finally, Teachers Retirement System of The State of Kentucky increased its stake in shares of Structure Therapeutics by 17.8% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock worth $589,000 after acquiring an additional 2,077 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.